JERSEY CITY, N.J. — June 16, 2020 — Intelligent software company for life science manufacturing, Apprentice.io, welcomes new investors to scale their solutions that steady pharma supply chains and get critical drugs to market in the wake of COVID-19.
As the novel coronavirus became a global pandemic, travel restrictions, site access limitations and personnel constraints disrupted pharma supply chains and threatened drug production. Apprentice experienced a 15x increase in usage as multiple life science organizations working on potential COVID-19 treatments or vaccines leveraged their software to collaborate at scale while restrictions remain in place.
Bringing a drug to market is an incredibly complex process that requires many stakeholders. The ability of these stakeholders to collaborate in the lab or manufacturing suite has been exceptionally difficult due to the pandemic. Apprentice site deployments have increased 6x since March due to their ability to provide a secure platform for pharma teams, subject matter experts, suppliers, FAT-SAT sites and contracted partners to connect and troubleshoot remotely, moving product development along efficiently.
While many manufacturing teams continue to work diligently to deliver COVID-19 treatments, everyday lifesaving products must still be brought to market as well. Those teams also rely on Apprentice solutions to ensure supply chain preservation since COVID-related manufacturing delays would create a chain reaction that could impact millions of patients in need of cancer treatments, diabetes medication, statins and others. Apprentice’s intelligent software alleviates that pressure.
“We immediately reassured our customers that we’re here to help them not just survive COVID, but to thrive, even at a time when it seems almost impossible,” said Angelo Stracquatanio, CEO & Co-founder of Apprentice.io.
Apprentice’s mission to support the life science industry caught the interest of global venture capital and private equity firm Insight Partners, who invested $7.5M to help scale the company’s mounting efforts.
“With the global pandemic ongoing, it is imperative for life science organizations to utilize technology and intelligent software to collaborate effectively and bring lifesaving drugs to patients in need at a faster pace,” said Nikhil Sachdev, Managing Director at Insight Partners. “Apprentice has developed a suite of regulatory-compliant solutions utilizing AI and machine learning to help companies streamline and speed up pharma manufacturing processes to ultimately help patients battling serious illnesses from COVID-19 to cancer. We are thrilled to partner with the Apprentice.io team as they continue on this important mission.”
Apprentice’s solutions include a regulatory-compliant intelligent software platform for life science manufacturing and an augmented reality, language independent, collaboration tool.
Apprentice’s intelligent software platform is an end-to-end solution for batch execution, augmented procedures, guided workflows, predictive resource management, event tracking and immersive training. The platform is enhanced with AI, machine learning and augmented reality, taking organizations beyond digitization and rapidly moving them into a new world of smart manufacturing. As a result, life science teams increase their speed to market, improve yield per batch and reduce deviations.
Their AR-enhanced remote collaboration tool, Tandem, allows organizations to communicate and troubleshoot remotely over a secure virtual platform. Subject matter experts can assist in-suite operators during critical moments so that sensitive project timelines are maintained while contracted partners and suppliers around the world can connect remotely to ensure that a drug product is transferred correctly between locations.
With facility access limited to key personnel, pharma teams are using Tandem and compliant, hands-free headsets, to troubleshoot in real-time with remote vendors for required maintenance performance, or during unforeseen equipment failures that threaten further delays. In addition, facility tours and inspections that have largely been suspended due to the pandemic can resume on a remote basis, accelerating approvals during a time when site access is extremely limited.
Apprentice.io has been shipping Rapid Deployment Kits to customer sites around the world, offering out-of-the-box intelligent software and collaboration solutions. Kits arrive pre-configured giving customers the ability to start using the product immediately, allowing them to use augmented reality and intelligent tools to execute smart procedures, collaborate in real-time, and perform remote reviews/approvals that streamline and speed up processes directly related to essential drug production.
“Critical treatments and products can’t wait,” Stracquatanio said. “We’re committed to doing whatever it takes to help the life science industry succeed during this global crisis.”
The New Jersey-founded company supports Fortune 100 clients in life sciences and other complex, compliance-driven industries across the U.S., Asia, South America and Europe.
Apprentice.io is an intelligent software company that builds solutions for global life science teams to increase speed to market, improve product yield and decrease deviations so that critical drugs get to market faster, with higher reliability. Run entire batch campaigns and leverage data for continuous process improvement and make your organization’s existing procedures with smart augmented data. Optimize supply chains and perform predictive consumable/raw material management, smart equipment tracking and preventive maintenance scheduling. Use language-independent global collaboration tools to elevate teams and seamlessly communicate in suite or out of suite, increasing speed to resolution and decreasing travel. Apprentice unlocks the power behind an organization’s data, delivering them to a new intelligent world of smart manufacturing. To learn more, visit www.apprentice.io or follow us on twitter @apprentice_io
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. For more information on Insight and all its investments, visit www.insightpartners.com or follow us on Twitter @insightpartners.